Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS
Foresee Pharmaceuticals has started patient dosing in a phase 2/3 trial of FP-025 in adults having severe to critical Covid-19 with associated acute respiratory distress syndrome (ARDS). According to the Taiwanese pharma company, FP-025 is an oral small molecule inhibitor of MMP-12, whose main functions are the modulation of various components such as elastin and […]